In support of this view are results derived from CRC patients treated with anthracyclines or oxaliplatin, known to promote ICD, demonstrating that favorable clinical outcomes associated with an increased number of cytotoxic CD8+ T cells within the tumor [34,35,36], whereas loss of DC function was a negative predictor of the therapeutic response to such agents in both clinical and preclinical settings [37,38]. Here, CD8A is linked to neoplasm.